Shaikh Rumana F, Ali Mohammed Taher, Mohsin Ashfaq A, Hiware Sanket D, Ahmad Arafat, Daimi Syed Rehan H, Moizuddin Khwaja, Shaikh Siraj A, Siddiqui Faiza B
Pharmacology, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Clinical Pharmacology, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Cureus. 2022 Jul 5;14(7):e26597. doi: 10.7759/cureus.26597. eCollection 2022 Jul.
Background Cardiovascular disease is a leading cause of morbidity and mortality. Therefore, it is essential to prevent cardiovascular diseases by correcting modifiable risk factors such as lowering lipid levels, lowering blood pressure, improving eating habits, giving up smoking, etc. The present study assessed the efficacy of herbal preparation containing ), , and - () in patients with hyperlipidemia. Methodology Patients were given extracts of 350 mg, 350 mg, 200 mg, Picrorhiza kurroa () 200 mg, and Piper nigrum () 5 mg. Unichem Laboratories, Mumbai, provided placebo tablets similar in shape and size to herbal tablets. Patients were assessed for compliance, and a complete lipid profile was done at DO, D15, D46, D76, and D106. In addition, total cholesterol and high-density lipoprotein-cholesterol (HDL-C) serum triglyceride were estimated by the respective methods throughout the study. Results The weight of the patients remained stable, the mean weight before being 65.42 ± 8.35 kg and after completion of the study being 65.42 ± 8.35 kg. There were no changes in the ECG during or after the drug therapy in any of the patients. Group A comprised nine patients, and group B had ten patients. Serum creatinine (mg %) was 0.94 and 0.95, fasting blood sugar mg (%) was 111.05 and 99.63, and postprandial blood sugar (mg %) was 150.89 and 147.94 on pre-treatment and post-treatment, respectively. The mean serum triglyceride levels in group A were 271.11, 261.11, 293.89, 167.22, and 128.89, and serum HDL- C levels were 46.11, 46.11, 54.44, 52.22, and 54.44. Serum triglyceride levels in group B were 268, 268.5, 202, 171, and 116, and serum HDL- C levels were 48.5, 48, 50, 50, and 53.5 on day 0, 15, 46, 76, and 106, respectively. A significant reduction in total cholesterol levels was observed on D46, D76, and D106, with a maximum reduction on D76 (25.36%). Similarly, a reduction in serum triglyceride was also observed on D46, D76, and D106, with a maximum reduction on D106 (52.02%). A significant difference was observed (P <0.05). There was also a significant reduction of low-density lipoprotein cholesterol (-) on D46, D76, and D106, with the maximum reduction on D76 (28.79%). There was a significant rise of HDL-C on D46 and D106, with a maximum rise on D106 (15.41%). A significant difference was observed (P <0.05). Conclusion The study drugs are safe and efficacious in reducing the total cholesterol, serum triglycerides, LDL-C levels, and increasing HDL-C levels.
背景 心血管疾病是发病和死亡的主要原因。因此,通过纠正可改变的危险因素,如降低血脂水平、降低血压、改善饮食习惯、戒烟等,来预防心血管疾病至关重要。本研究评估了含有[具体成分1]、[具体成分2]和[具体成分3]的草药制剂对高脂血症患者的疗效。
方法 给予患者[具体成分1]提取物350毫克、[具体成分2]提取物350毫克、[具体成分3]提取物200毫克、胡黄连提取物200毫克和黑胡椒提取物5毫克。孟买的优尼康实验室提供了形状和大小与草药片剂相似的安慰剂片剂。评估患者的依从性,并在第0天、第15天、第46天、第76天和第106天进行完整的血脂谱检测。此外,在整个研究过程中,通过各自的方法测定总胆固醇、高密度脂蛋白胆固醇(HDL-C)和血清甘油三酯。
结果 患者体重保持稳定,治疗前平均体重为65.42±8.35千克,研究结束后为65.42±8.35千克。在任何患者的药物治疗期间或之后,心电图均无变化。A组有9名患者,B组有10名患者。治疗前和治疗后的血清肌酐(毫克%)分别为0.94和0.95,空腹血糖(毫克%)分别为111.05和99.63,餐后血糖(毫克%)分别为150.89和147.94。A组的平均血清甘油三酯水平分别为271.11、261.11、293.89、167.22和128.89,血清HDL-C水平分别为46.11、46.11、54.44、52.22和54.44。B组在第0天、第15天、第46天、第76天和第106天的血清甘油三酯水平分别为268、268.5、202、171和116,血清HDL-C水平分别为48.5、48、50、50和53.5。在第46天、第76天和第106天观察到总胆固醇水平显著降低,在第76天降低最多(25.36%)。同样,在第46天、第76天和第106天也观察到血清甘油三酯降低,在第106天降低最多(52.02%)。观察到显著差异(P<0.05)。在第46天、第76天和第106天,低密度脂蛋白胆固醇(LDL-C)也显著降低,在第76天降低最多(28.79%)。在第46天和第106天,HDL-C显著升高,在第106天升高最多(15.41%)。观察到显著差异(P<0.05)。
结论 研究药物在降低总胆固醇、血清甘油三酯、LDL-C水平以及升高HDL-C水平方面是安全有效的。